Zavesca
What Zavesca is used for
Zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable. Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type-C disease.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Zavesca
- Active substance
- miglustat
- Disease area
- Gaucher Disease; Niemann-Pick Diseases
- Medicine group
- Other alimentary tract and metabolism products
- ATC code
- A16AX06
- Marketing authorisation holder
- Advanz Pharma Limited
- Authorised in the EU since
- 2002
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zavesca used for?
Zavesca is indicated for the oral treatment of adult patients with mild to moderate type-1 Gaucher disease. Zavesca may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable. Zavesca is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type-C disease.
What is the active substance in Zavesca?
Zavesca contains miglustat.
Who makes Zavesca?
The EU marketing authorisation holder is Advanz Pharma Limited.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU